Integrated network pharmacology and molecular docking approaches to reveal the synergistic mechanism of multiple components in *Venenum Bufonis* for ameliorating heart failure

Wei Ren¹*, Zhiqiang Luo²*, Fulu Pan³*, Jiali Liu¹, Qin Sun¹, Gang Luo¹, Raoqiong Wang⁴, Haiyu Zhao⁴, Baolin Bian⁴, Xiao Xiao⁵, Qingrong Pu¹, Sijin Yang¹ and Guohua Yu²

¹National Traditional Chinese Medicine Clinical Research Base, Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China

²School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China

³School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China

⁴Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China

⁵Beijing National Laboratory for Molecular Sciences, Key Laboratory of Analytical Chemistry for Living Biosystems, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, Beijing, China

*These authors contributed equally to this work.

**ABSTRACT**

*Venenum Bufonis* (VB), also called Chan Su in China, has been extensively used as a traditional Chinese medicine (TCM) for treating heart failure (HF) since ancient time. However, the active components and the potential anti-HF mechanism of VB remain unclear. In the current study, the major absorbed components and metabolites of VB after oral administration in rats were first collected from literatures. A total of 17 prototypes and 25 metabolites were gathered. Next, a feasible network-based pharmacological approach was developed and employed to explore the therapeutic mechanism of VB on HF based on the collected constituents. In total, 158 main targets were screened out and considered as effective players in ameliorating HF. Then, the VB components–main HF putative targets–main pathways network was established, clarifying the underlying biological process of VB on HF. More importantly, the main hubs were found to be highly enriched in adrenergic signalling in cardio-myocytes. After verified by molecular docking studies, four key targets (ATP1A1, GNAS, MAPK1 and PRKCA) and three potential active leading compounds (bufotalin, cinobufaginol and 19-oxo-bufalin) were identified, which may play critical roles in cardiac muscle contraction. This study demonstrated that the integrated strategy based on network pharmacology and molecular docking was helpful to uncover the synergistic mechanism of multiple constituents in TCM.

**Subjects** Bioinformatics, Molecular Biology, Drugs and Devices, Pharmacology, Computational Science

**Keywords** *Venenum Bufonis*, Heart failure, Network pharmacology, Molecular docking

How to cite this article Ren W, Luo Z, Pan F, Liu J, Sun Q, Luo G, Wang R, Zhao H, Bian B, Xiao X, Pu Q, Yang S, Yu G. 2020. Integrated network pharmacology and molecular docking approaches to reveal the synergistic mechanism of multiple components in *Venenum Bufonis* for ameliorating heart failure. PeerJ 8:e10107 http://doi.org/10.7717/peerj.10107
INTRODUCTION

Heart failure (HF), a multifactorial degenerative disease, occurs when the heart is not able to pump blood efficiently to satisfy the oxygen and nutritional needs of the body (Asano et al., 2019). HF affects over 26 million people worldwide and continues to represent a major burden for public health due to its high mortality, morbidity and healthcare expenses (Di Palo & Barone, 2020; Lother & Hein, 2016). The incidence rate of HF rises in magnitude with age and the major etiologies were coronary heart disease, abnormal heart valves and hypertension (Akkineni et al., 2019). Western medicines, such as angiotensin converting enzyme (ACE) inhibitors, diuretics, β-adrenergic blockers, angiotensin receptor I antagonists and positive inotropic agents, are currently the main treatment programs for HF (Xu et al., 2020; Yang et al., 2020a; Yang et al., 2020b). However, long-term use of these chemical drugs will lead to a series of adverse reactions like electrolyte depletion, fluid depletion, and hypotension (Jia et al., 2020). Therefore, novel alternative or synergetic anti-HF therapies are greatly needed.

Venenum Bufonis (VB) is the dried white secretion of the auricular and skin glands of Bufo bufo gargarizans Cantor or Bufo melanostictus Schneider (He et al., 2019; Yun et al., 2009). As a precious traditional Chinese medicine (TCM), VB has long been used for treating heart failure, arrhythmia, swells, sore throat, pains, cancers and many other diseases (Liang et al., 2008; Pan et al., 2020). Extensive natural product studies have indicated that VB contains a high level of bufadienolides and many other constituents like alkaloids, cyclic amides, sterols, polypeptides, proteins, polysaccharides, and organic acids (Wei et al., 2019). Modern pharmacological studies have confirmed that VB exhibited a variety of pharmacological effects, including cardiotonic, antinociceptive, anti-tumor, anesthetic, anti-inflammatory as well as antimicrobial properties (Wei et al., 2020). Importantly, it is evident that VB exerts a strong cardiac excitatory effect like that of digitals, and the drug possesses many advantages such as no accumulation, quick-acting and diuretic action (Wei et al., 2019). According to the Chinese Pharmacopoeia (2015 edition), VB is contained in many TCM prescriptions for the treatment of HD, such as Jiuxin Pill and Shexiang Baoxin Pill (Chinese Pharmacopoeia Commission, 2015). Although well-practiced in clinical medicine, the holistic pharmacological mechanisms of VB on HF are largely unknown.

As an emerging field of pharmacology, network pharmacology delivers a systematic and holistic understanding of drug action and disease complexity, which shares key ideas with the integrality and systematicness of TCM theory (Luo et al., 2020; Zhang et al., 2020). An increasing body of evidence suggests that network pharmacology is a powerful tool to illuminate the integration synergistic mechanism of action of TCM from the multi-dimensional perspective (Chen et al., 2019; Miao et al., 2019). For example, the bioactive candidates and underlying mechanisms of Cichorium glandulosum for ameliorating type 2 diabetes mellitus was successfully elucidated using “compound-target” network analysis (Qin et al., 2019). The action mechanism of Carthamus tinctorius L. on cardiovascular disease was also elaborated based on the “compound-protein/gene-disease” network (Yu et al., 2019). However, due to the limitation of this method, many previous researches usually collected TCM components from related TCM databases to establish the compound–target
map. The candidate compounds might not be in line with the components actually delivered into the blood circulatory system, which unavoidably produced unreal results (Ding et al., 2019; Zhang et al., 2018).

In this study, first the in vivo ingredients of VB after oral administration in rats were taken from the literature. Second, the VB- and HF-associated targets were predicted. Third, network construction and pathway enrichment analysis were used to explore the active components and the potential targets relevant to the treatment of HF with VB. Finally, molecular docking was performed to confirm the specific interactions between VB and the candidate targets. The above study not only provides a comprehensive understanding about the molecular mechanism of VB acting on HF, but also offers a rapid and effective strategy for screening desired compounds from TCM. The flowchart was illustrated in Fig. 1.

**MATERIALS AND METHODS**

**In vivo constituents of VB**

A total of 42 in vivo constituents of VB have been reported, including 17 prototypes and 25 metabolites (He et al., 2012; Liang et al., 2008; Miyashiro, Nishio & Shimada, 2008; Ning et al., 2010; Tao et al., 2017; Xia et al., 2010; Xin et al., 2016; Zhu et al., 2013). The molecular 2D files of these constituents were downloaded from the ChemSpider database (http://www.chemspider.com/) and were saved in mol format (step 1 in Fig. S1). The details were listed in Table S1.

**The prediction of VB-related targets**

The predicted proteins targeted by the in vivo constituents of VB were screened from MedChem Studio (MedChem Studio, 3.0; Simulations Plus, Inc, Lancaster, CA, USA, 2012). This software could efficiently capture the FDA-approved drugs that have similar chemical structures to the components in TCM (Yu et al., 2016). We picked out VB compound-drug pairs with high confidence scores (≥0.6) and considered the target proteins of the known drugs as the VB-related targets. Other parameters were set as the default values (step 1 in Fig. S1).

**Known therapeutic targets for HF**

In this study, two databases were employed in acquiring pathological targets for HF, by use of “heart failure” as the query. One was the DrugBank database (http://www.drugbank.ca/, version 5.1.1), which could provide detailed information on the drug targets and their links with human diseases (Griesenauer, Schillebeeckx & Kinch, 2019). Only drug–target interactions for FDA-approved anti-HF drugs and potential human protein targets associated with HF were selected for further analysis. The second platform was the Online Mendelian Inheritance in Man (OMIM) database (http://www.omim.org/, updated on May 4, 2018), a constantly updated database of human genetic diseases and genes (step 1 in Fig. S1) (Hamosh et al., 2005).
**Protein–protein interaction (PPI) data**

The PPI information related to the putative targets of VB constituents and known therapeutic targets for HF was harvested by use of STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) database ([http://string-db.org/](http://string-db.org/)). This database could provide a global perspective of proteins and their functional interactions and associations ([Jensen et al., 2009](http://string-db.org/)). Results were limited to “Homo sapiens” and protein interactions with a confidence score greater than or equal to 0.4 would be selected. Other parameters were set as the default values (step 2 in Fig. S1).
Network construction and analysis
In order to illustrate the interaction among the ingredients, targets and diseases, a “ingredient–target–disease” network was built by introducing the information of candidate compounds of VB, putative targets of VB and HF-associated targets into Cytoscape software (version 3.6.0, Boston, MA, USA). This software is an efficient open source bioinformatics tool for visualizing and analysing the complex biological networks (Shannon et al., 2003). Three important topological characteristics (“degree”, “betweenness”, and “closeness”), which have been described in our previous publication (Yu et al., 2018), were calculated to assess the central attribute of each hub node in the network by use of the Cytoscape plugin “Network Analyzer”. And “degree” > median degree centrality, “betweenness” > median betweenness centrality and “closeness” > median closeness centrality were adopted as the screening criteria to acquire the critical targets (Luo et al., 2020). Other parameters were set as the default values (step 2 in Fig. S1).

Pathway enrichment analysis
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways analysis and Gene Ontology (GO) enrichment analysis were undertaken to explore the potential functions of the pivotal target proteins involved in the VB-mediated treatment of HF (Nguyen et al., 2019a; Nguyen et al., 2019b), by use of the Database for Annotation, Visualization and Integrated Discovery (DAVID) system (http://david.abcc.ncifcrf.gov/home.jsp/, v6.8) (Dennis Jr et al., 2003). Relevant pathways with the false discovery rate (FDR)-corrected P-value < 0.05 were considered statistically significant. Other parameters were set as the default values (step 3 in Fig. S1).

Molecular docking simulation
Molecular docking studies were conducted to further verify the reliability of the potential targets using CDOCKER module implemented in Discovery Studio 2016 (DS 2016). CDOCKER is a semi-flexible molecular docking analysis method based on the CHARMm force field, which can produce high-precision docking results, and it provides information on the interaction binding energy and ligand–receptor docking mode. The three-dimensional (3D) structures of the candidate compounds were generated using Chem3D Pro 12.0 and the crystallographic structures of the proteins encoded by the candidate target genes were obtained from the PDB database (http://www.rcsb.org/pdb/home/home.do), which was then decorated by removing the ligands, adding hydrogen, removing water, optimizing and patching amino acids. The binding site was defined by the ligand atoms, and the radius range was automatically generated. After each compound was docked, the 10 best conformations were obtained (Yang, 2020). Finally, CDOCKER interaction energies (CIEs) were used to assess the binding affinities between the core targets and the corresponding compounds. And the conformation corresponding to the lowest CIE was selected as the most probable binding conformation. All parameters used in calculation were default except for explained (step 4 in Fig. S1).
RESULTS AND DISCUSSION

Putative targets for VB
As shown in Table S2, a total of 260 potential targets of the in vivo components of VB were obtained by MedChem Studio. The results showed that the candidate compounds could act on multiple targets, and one target could also be linked to multiple components.

Known therapeutic targets for HF
We collected 109 and 199 HF-related targets from DrugBank database and OMIM database, respectively. We then checked the data and eliminate redundant entries, leaving a final dataset of 292 targets associated with HF (Table S3). Among them, 22 targets were both the VB- and HF-related targets, including NR1I2, MT-CO1, CA2, NR3C1, SHBG, ATP1A1, CYP17A1, PGR, NR3C2, MME, AR, ACE, PRKCA, CYP11B2, RXRA, PPARG, PIK3CG, PPARD, PDE4B, KCNMA1, MED1 and HIF1A.

Network and pathway analysis
To facilitate scientific interpretation of the complex relationships between VB and HF, a “chemical target-disease associated gene” network, comprising the VB-related targets and the HF-related targets, was constructed based on the PPI data from STRING database. As listed in Table S4, this network was composed of 461 nodes and 5009 edges. After computing the values of the topological features of all hubs, 158 major hubs were identified because they satisfied the criteria (degree cutoff = 19, betweenness cutoff = 0.001659, and closeness cutoff = 0.381426). Among them, 93 hubs were VB-related targets, 65 hubs were HF-related targets. These major hubs may play a critical role in the entire interaction network. The specific information about the major hubs was shown in Table S5.

Potential mechanisms of VB in treating HF
To elucidate the biological process (BP), molecular function (MF), cellular components (CC) of these major hubs involved in, GO enrichment analysis was conducted on the major hubs. As shown in Figs. 2A–2C, the top 10 significant GO entries ($P < 0.05$) were selected on the basis of $P$ value.

To deeply determine the function and systemic association of the main hubs, KEGG pathway enrichment analysis were conducted. The results indicated that these hubs were enriched in 101 significant pathways ($P < 0.05$). As shown in Fig. 2D, the top 11 pathways were considered as the main biological processes involved in the treatment. To further identify the functional mechanisms of VB on HF, the candidate compounds-main VB-related targets-main pathways network diagram was generated and elucidated in Fig. 3. The hubs can be mainly divided into the following three functional modules (circles): signal transduction (including adrenergic signalling in cardio-myocytes, calcium signalling pathway, cAMP signalling pathway, dilated cardiomyopathy, long-term potentiation and cGMP-PKG signalling pathway), cardiovascular system (including cardiac muscle contraction, vascular smooth muscle contraction and hypertrophic cardiomyopathy), and neural regulation (including dopaminergic synapse and circadian entrainment). Interestingly, adrenergic signalling in cardio-myocytes was highly enriched in KEGG.
pathway analysis, which played a critical role in the regulation of cardiac muscle contraction (the top-ranked GO: Biological Process terms), suggesting that VB may impart therapeutic effects on HF majorly through adrenergic signalling in cardio-mycocytes.

As shown in Table S6, the VB putative targets associated with adrenergic signalling in cardio-mycocytes include guanine nucleotide-binding protein G(s) subunit alpha (GNAS), adenylate cyclase 2 (ADCY2), ADCY5, protein phosphatase 1 catalytic subunit gamma (PPPI1C), protein phosphatase 2 catalytic subunit alpha (PPP2CA), protein phosphatase 2 catalytic subunit beta (PPP2CB), calcium voltage-gated channel subunit alpha1 C (CACNA1C), CACNA1D, ATPase Na+/K+ transporting subunit alpha 1 (ATP1A1), mitogen-activated protein kinase 1 (MAPK1), protein kinase C alpha (PRKCA). Figure 4 depicts a graphical overview of adrenergic signalling in cardio-mycocytes influenced by main putative targets of VB components.

**Molecular docking**

Table 1 displayed the CIEs (top 5 for each target) of VB hit constituents against the active sites of the screened targets in adrenergic signalling, including ATP1A1, GNAS, ADCY2, ADCY5, PPP1CC, PPP2CA, PPP2CB, CACNA1C, CACNA1D, MAPK1 and PRKCA. The results indicated that the VB-related components had been docked successfully with

---

**Figure 2**  GO term performance and pathway enrichment analysis of the major hubs. (A) GO: BP; (B) GO: MF; (C) GO: CC; and (D) KEGG. The ordinate stands for GO terms or the main pathways, the primary abscissa stands for minus log 10(P), and the secondary abscissa stands for the percentage of major hubs involved in the corresponding GO terms or the main pathways out of total major hubs.

Full-size DOI: 10.7717/peerj.10107/fig-2
Hypertrophic cardiomyopathy

Figure 3 VB ingredients-major hubs-pathway network. Green V-diagrams represent each prototype component in VB; yellow V-diagrams represent each metabolite in VB; round blue nodes represent putative targets of components in VB; round red nodes represent known therapeutic targets for HF; orange rectangles represent top 11 pathways from enrichment analysis of major targets; edges represent interactions among VB ingredients, putative targets, known therapeutic targets for the treatment of VB, and main pathways.

Figure 4 Adrenergic signalling in cardiomyocytes influenced by major putative targets of VB components.
Table 1  Molecular docking results (top five for each target).

| Targets    | Compound                                      | -CIE (kcal/mol) |
|------------|-----------------------------------------------|-----------------|
| ATP1A1     | Bufotalin                                     | 49.0335         |
|            | Cinobufotalin                                 | 46.109          |
|            | Cinobufagin                                   | 45.1269         |
|            | Cinobufaginol                                 | 44.0494         |
|            | 5β, 6α-dihydroxybufalin                       | 43.3908         |
| GNAS       | Cinobufaginol                                 | 55.2668         |
|            | 6α-hydroxybufalin                             | 53.1182         |
|            | 19-oxo-desacetylicinobufagin                  | 52.2151         |
|            | 1,5-dihydroxylidesacetylicinobufagin          | 49.9538         |
|            | 1,12β-dihydroxycinobufagin                   | 49.4652         |
| MAPK1      | Cinobufaginol                                 | 55.1432         |
|            | Cinobufagin                                  | 54.0654         |
|            | Bufotalin                                    | 53.1891         |
|            | 1,5-dihydroxylidesacetylicinobufagin          | 51.5985         |
|            | 12-hydroxyl-cinobufagin                      | 51.2183         |
| PRKCA      | 19-oxo-bufalin                                | 42.0454         |
|            | Marinobufagin                                 | 39.3428         |
|            | Hellebrigenin                                 | 38.6171         |
|            | 5β, 6α-dihydroxybufalin                       | 37.9654         |
|            | Resibufogenin                                 | 37.8932         |

ATP1A1, GNAS, MAPK1 and PRKCA, which may be the key targets involved in VB for the treatment of HF. Herein, we selected four representative pairs of binding interactions to illustrate how the four targets bound to their corresponding components (Fig. 5). The interplay between ATP1A1 and bufotalin was depicted in Figs. 5A and 5B. The hydroxyl groups on bufotalin could form three hydrogen bonds with SER209, ARG191 and VAL712. Another key residue which involved in interaction was MET157. The binding mode of GNAS and cinobufaginol was depicted in Figs. 5C and 5D. The hydroxyl groups could bind with LEU171, MET255, ASN254 and LYS300 by forming hydrogen bonds. The carbonyl on the lactone ring could also form hydrogen bond with LYS305. In addition, the lactone ring could bind with GLU164 and LYS305 via pi-anion and pi-cation interactions. Other interactions including alkyl and pi-alkyl were connected with ALA303, TYR163 and LEU296. The action mode of MAPK1 and cinobufaginol was depicted in Figs. 5E and 5F. Cinobufaginol could form five hydrogen bonds with LYS112, LYS52 and TYR34. In addition, the lactone ring could bind with ASP109 via pi-anion interaction. Other interactions including alkyl and pi-alkyl were connected with VAL37. The interplay between PRKCA and 19-oxo-bufalin was depicted in Figs. 5G and 5H. The hydroxyl groups of 19-oxo-bufalin could form two hydrogen bonds with PRO202 and LYS230. Another key residue which involved in interaction was LEU200.
Figure 5  The binding modes of the selected compounds and targets. (A) Schematic (3D) representation and (B) Schematic (2D) representation of the interplay between bufotalin and ATP1A1 (PDB ID:chimeric 3N23). (C) Schematic (3D) representation and (D) Schematic (2D) representation of the interplay between cinobufaginol and GNAS (PDB ID:chimeric 3C14). (E) Schematic (3D) representation and (F) Schematic (2D) representation of the interplay between cinobufaginol and MAPK1 (PDB ID:chimeric 3O71). (G) Schematic (3D) representation and (H) Schematic (2D) representation of the interplay between 19-oxo-bufalin and PRKCA (PDB ID:chimeric 4DNL). Active site amino acid residues were represented as tubes, while the compounds were shown as a stick model with purple color.

Full-size DOI: 10.7717/peerj.10107/fig-5
DISCUSSION

Many pathways are involved in adrenergic signalling for the regulation of cardiac contractile function. Among them, the best described is the mechanism mediated by β-adrenergic receptor (β-AR)–Gs–adenylate cyclase (AC) pathway (Baker, 2014). Activation of β-AR–Gs–AC plays an important role in increasing heart rate and force of myocardial contraction (Chen et al., 2020; Santulli & Iaccarino, 2016). According to our predicted results, VB could regulate β-AR–Gs–AC pathway by targeting Gs (GNAS) and AC (ADCY2 and ADCY5). The regulation of Ca$^{2+}$ homeostasis is also important for the cardio-myocyte excitation and cardiac electrical activity (Arakelyan et al., 2007). According to our predicted results, VB could regulate by targeting PP1 (PPP1CC), PP2A (PPP2CA, PPP2CB), and LTCC (CACNA1C, CACNA1D). Na$^+$/K$^+$-ATPase, a ubiquitous membrane protein composed of two subunits denoted as α and β, is also a critical regulator in maintaining the balance of Ca$^{2+}$ in cardio-myocytes (Orlov et al., 2020; Šeflová et al., 2017). An increasing body of evidence suggests that bufadienolides in VB possess inhibition effects on Na$^+$/K$^+$-ATPase (Orlov et al., 2020; Sousa et al., 2017), such as bufalin (Lan et al., 2018; Laursen et al., 2015), cinobufagin (Wang, Sun & Heinbockel, 2014), marinobufagenin (Strauss et al., 1993), and hellebrigenin (Moreno et al., 2013). Therefore, the cardiotonic effect of VB may be mainly through the suppression of Na$^+$/K$^+$-ATPase. Inhibition of the Ca$^{2+}$/PKC α/ERK1/2 signal pathway plays a significant role in attenuating the progression of heart failure (Braz et al., 2004; Molkentin & Robbins, 2009). Several components from VB have been reported to inhibit the activity PKCα and ERK, such as bufalin (Wu et al., 2015), marinobufagin (Bagrov et al., 2000; Fedorova et al., 2003) and cinobufagin (Baek et al., 2015).

Based on the data analysis above, the bufadienolides may be the main active components in VB, which exert anti-HF effects via synergistically acting on multiple targets in multiple pathways. Among them, the positive inotropic effect of VB produced through the inhibition of Na$^+$/K$^+$-ATPase has been demonstrated in many basic researches and clinical practices. The molecular docking results indicated that the representative compounds could connect with the active-site residues via various noncovalent interactions, including the hydrogen bonding, pi-alkyl, pi-anion and pi-cation, etc, which was valuable for understanding of the action mechanisms of VB. In addition, according to -CIE values, bufotalin, cinobufaginol and 19-oxo-bufalin showed the best performance and thus were considered as the potential active leading compounds of the corresponding targets. Further researches on other potential targets or pathways are required to validate the predicted results.

CONCLUSION

In summary, the active components of VB and their synergistic mechanisms for alleviating HF were successfully unveiled by network pharmacology coupled with molecular docking approach. The adrenergic signaling involved in cardiac muscle contraction process was found to be mainly responsible for the anti-HF effect of VB in silico. Four core targets and their corresponding leading compounds were identified, which may provide valuable information for further experimental validations and drug discovery.
ADDITIONAL INFORMATION AND DECLARATIONS

Funding
This work was supported by the National Traditional Chinese Medicine Clinical Research Base (Grant NO. [2020]33). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures
The following grant information was disclosed by the authors:
National Traditional Chinese Medicine Clinical Research Base: [2020]33.

Competing Interests
The authors declare there are no competing interests.

Author Contributions
• Wei Ren, Zhiqiang Luo and Fulu Pan performed the experiments, authored or reviewed drafts of the paper, and approved the final draft.
• Jiali Liu, Qin Sun, Gang Luo, Raoqiong Wang and Qingrong Pu analyzed the data, prepared figures and/or tables, and approved the final draft.
• Haiyu Zhao and Baolin Bian performed the experiments, authored or reviewed drafts of the paper, provide software, and approved the final draft.
• Xiao Xiao analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
• Sijin Yang and Guohua Yu conceived and designed the experiments, authored or reviewed drafts of the paper, and approved the final draft.

Data Availability
The following information was supplied regarding data availability:
The raw data are available in the Supplemental Files.

Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.10107#supplemental-information.

REFERENCES

Akkineni S, Mohammed O, Pathiraj J, Devasia T, Chandrababu R, Kunhikatta V. 2019. Readmissions and clinical outcomes in heart failure patients: a retrospective study. Clinical Epidemiology and Global Health 8:495–500 DOI 10.1016/j.cegh.2019.11.002.

Arakelyan KP, Sahakyan YA, Hayrapetyan LR, Khudaverdyan DN, Ingelman-Sundberg M, Mkrtchian S, Ter-Markosyan AS. 2007. Calcium-regulating peptide hormones and blood electrolytic balance in chronic heart failure. Regulatory Peptides 142(3):95–100 DOI 10.1016/j.regpep.2007.02.001.
Asano R, Abshire M, Dennison-Himmelfarb C, Davidson PM. 2019. Barriers and facilitators to a 'good death' in heart failure: an integrative review. Collegian 26(6):651–665 DOI 10.1016/j.colegn.2019.09.010.

Baek SH, Kim C, Lee JH, Nam D, Lee J, Lee SG, Chung WS, Jang HJ, Kim SH, Ahn KS. 2015. Cinobufagin exerts anti-proliferative and pro-apoptotic effects through the modulation ROS-mediated MAPKs signaling pathway. Immunopharmacology and Immunotoxicology 37(3):265–273 DOI 10.3109/08923973.2015.1027916.

Bagrov AY, Dmitrieva RI, Dorofeeva NA, Fedorova OV, Lopatin DA, Lakatta EG, Droy-Lefaix MT. 2000. Cicletanine reverses vasoconstriction induced by the endogenous sodium pump ligand, marinobufagenin, via a protein kinase C dependent mechanism. Journal of Hypertension 18(2):209–215 DOI 10.1097/00004872-200018020-00012.

Baker AJ. 2014. Adrenergic signaling in heart failure: a balance of toxic and protective effects. Pflugers Archiv: European Journal of Physiology 466(6):1139–1150 DOI 10.1007/s00424-014-1491-5.

Braz JC, Gregory K, Pathak A, Zhao W, Sahin B, Klevitsky R, Kimball TF, Lorenz JN, Nairn AC, Liggett SB, Bodi I, Wang S, Schwartz A, Lakatta EG, DePaoli-Roach AA, Robbins J, Hewett TE, Bibb JA, Westfall MV, Kranias EG, Molkentin JD. 2004. PKC-α regulates cardiac contractility and propensity toward heart failure. Nature Medicine 10(3):248–254 DOI 10.1038/nm1000.

Chen S, Guo W, Qi X, Zhou J, Liu Z, Cheng Y. 2019. Natural alkaloids from lotus plumule ameliorate lipopolysaccharide-induced depression-like behavior: integrating network pharmacology and molecular mechanism evaluation. Food & Function 10(9):6062–6073 DOI 10.1039/c9fo01092k.

Chen JJ, Marsden AN, Scott CA, Akimzhanov AM, Boehning D. 2020. DHHC5 mediates β-adrenergic signaling in cardiomyocytes by targeting Ga proteins. Biophysical Journal 118(4):826–835 DOI 10.1016/j.bpj.2019.08.018.

Chinese Pharmacopoeia Commission. 2015. Pharmacopoeia of People’s Republic of China part I. Beijing: People’s Medical Publishing House.

Cruz Jdos S, Matsuda H. 1993. Arenobufagin, a compound in toad venom, blocks Na(+)–K+ pump current in cardiac myocytes. European Journal of Pharmacology 239(1–3):223–226 DOI 10.1016/0014-2999(93)90999-x.

Dennis Jr G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. 2003. DAVID: database for annotation, visualization, and integrated discovery. Genome Biology 4(5):P3–P3 DOI 10.1186/gb-2003-4-5-p3.

Di Palo KE, Barone NJ. 2020. Hypertension and heart failure: prevention, targets, and treatment. Heart Failure Clinics 16(1):99–106 DOI 10.1016/j.hfc.2019.09.001.

Ding M, Ma W, Wang X, Chen S, Zou S, Wei J, Yang Y, Li J, Yang X, Wang H, Li Y, Wang Q, Mao H, Gao X, Chang Y. 2019. A network pharmacology integrated pharmacokinetics strategy for uncovering pharmacological mechanism of compounds absorbed into the blood of Dan-Lou tablet on coronary heart disease. Journal of Ethnopharmacology 242:Article 112055 DOI 10.1016/j.jep.2019.112055.
Fedorova OV, Talan MI, Agalakova NI, Droy-Lefaix MT, Lakatta EG, Bagrov AY. 2003. Myocardial PKC beta2 and the sensitivity of Na/K-ATPase to marinobufagenin are reduced by cicletanine in Dahl hypertension. *Hypertension* **41**(3):505–511 DOI 10.1161/01.Hyp.0000053446.43894.9f.

Griesenauer RH, Schillebeeckx C, Kinch MS. 2019. Assessing the public landscape of clinical-stage pharmaceuticals through freely available online databases. *Drug Discovery Today* **24**(4):1010–1016 DOI 10.1016/j.drudis.2019.01.010.

Hamosh A, Scott AF, Amberger JS, Bocchini CA, McKusick VA. 2005. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. *Nucleic Acids Research* **33**:D514–D517 DOI 10.1093/nar/gki033.

He X, Hu H, Wu Y, Zeng X. 2012. Urinary metabolites of cinobufagin in rats and their antiproliferative activities. *Natural Product Research* **26**(6):489–499 DOI 10.1080/14786419.2010.510798.

He R, Ma H, Zhou J, Zhu Z, Lv X, Li Q, Wang H, Yan Y, Luo N, Di L, Wu Q, Duan J. 2019. High resolution mass profile of bufadienolides and peptides combing with anti-tumor cell screening and multivariate analysis for the quality evaluation of bufonis venenum. *Molecules* **24**(10):Article 1943 DOI 10.3390/molecules24101943.

Jensen L, Kuhn M, Stark M, Chaffron S, Creevey C, Muller J, Doerks T, Julien P, Roth A, Simonovic M, Bork P, Von Mering C. 2009. STRING 8—a global view on proteins and their functional interactions in 630 organisms. *Nucleic Acids Research* **37**:D412–D416 DOI 10.1093/nar/gkn760.

Jia Q, Wang L, Zhang X, Ding Y, Li H, Yang Y, Zhang A, Li Y, Lv S, Zhang J. 2020. Prevention and treatment of chronic heart failure through traditional Chinese medicine: role of the gut microbiota. *Pharmacological Research* **151**:Article 104552 DOI 10.1016/j.phrs.2019.104552.

Lan Y, Wang X, Lou J-C, Xing J-S, Yu Z, Wang H, Zou S, Ma X, Zhang B. 2018. Bufalin inhibits glioblastoma growth by promoting proteasomal degradation of the Na(+)K(+) ATPase α1 subunit. *Biomedicine & Pharmacotherapy* **103**:204–215 DOI 10.1016/j.biopha.2018.04.030.

Laursen M, Gregersen JL, Yatime L, Nissen P, Fedosova N. 2015. Structures and characterization of digoxin- and bufalin-bound Na+, K+-ATPase compared with the ouabain-bound complex. *Proceedings of the National Academy of Sciences of the United States of America* **112**(6):1755–1760 DOI 10.1073/pnas.1422997112.

Liang Y, Liu A, Qin S, Sun J, Yang M, Li P, Guo D. 2008. Simultaneous determination and pharmacokinetics of five bufadienolides in rat plasma after oral administration of Chansu extract by SPE-HPLC method. *Journal of Pharmaceutical and Biomedical Analysis* **46**(3):442–448 DOI 10.1016/j.jpba.2007.11.001.

Lother A, Hein L. 2016. Pharmacology of heart failure: from basic science to novel therapies. *Pharmacology & Therapeutics* **166**:136–149 DOI 10.1016/j.pharmthera.2016.07.004.

Luo Z, Yu G, Chen X, Liu Y, Zhou Y, Wang G, Shi Y. 2020. Integrated phytochemical analysis based on UHPLC-LTQ-Orbitrap and network pharmacology approaches
to explore the potential mechanism of Lycium ruthenicum Murr. for ameliorating Alzheimer’s disease. *Food & Function* **11**(2):1362–1372 DOI 10.1039/c9fo02840d.

Miao X, Zheng L, Zhao Z, Su S, Zhu , Guo J, Shang E, Qian D, Duan J. 2019. Protective effect and mechanism of boswellic acid and myrrha sesquiterpenes with different proportions of compatibility on neuroinflammation by LPS-induced BV2 cells combined with network pharmacology. *Molecules* **24**(21): Article 3946 DOI 10.3390/molecules24213946.

Miyashiro Y, Nishio T, Shimada K. 2008. Characterization of in vivo metabolites of toad venom using liquid chromatography-mass spectrometry. *Journal of Chromatographic Science* **46**(6):534–538 DOI 10.1093/chromsci/46.6.534.

Molkentin J, Robbins J. 2009. With great power comes great responsibility: using mouse genetics to study cardiac hypertrophy and failure. *Journal of Molecular and Cellular Cardiology* **46**(2):130–136 DOI 10.1016/j.yjmcc.2008.09.002.

Moreno Y, Katz A, Miklos W, Cimmino A, Tal D, Ainbinder E, Zehl M, Urban E, Evidente A, Kopp B, Berger W, Feron O, Karlsh S, Kiss R. 2013. Hellebrin and its aglycone form hellebrigenin display similar in vitro growth inhibitory effects in cancer cells and binding profiles to the alpha subunits of the Na+/K+-ATPase. *Molecular Cancer* **12**:Article 33 DOI 10.1186/1476-4598-12-33.

Nguyen QK, Edward K, Nagasundaram N, Matthew C, Yeh HY. 2019a. Computational identification of vesicular transport proteins from sequences using deep gated recurrent units architecture. *Computational and Structural Biotechnology Journal* **17**:1245–1254 DOI 10.1016/j.csbj.2019.09.005.

Nguyen QK, Edward K, Nagasundaram N, Matthew C, Yeh HY. 2019b. ET-GRU: using multi-layer gated recurrent units to identify electron transport proteins. *BMC Bioinformatics* **20**:377 DOI 10.1186/s12859-019-2972-5.

Ning J, Wu T, Tian Y, Wang C, Tian G, Zhang B, Liu K, Ma X. 2010. Identification of cinobufagin metabolites in the bile of rats. *Xenobiotica* **40**(1):48–54 DOI 10.3109/00498250903331049.

Orlov SN, Tverskoi AM, Sidorenko SV, Smolyaninova LV, Lopina OD, Dulin NO, Klimanova EA. 2020. NA, K-ATPase as a target for endogenous cardiotonic steroids: what’s the evidence? *Genes & Diseases* Epub ahead of print Jan 22 2020 DOI 10.1016/j.gendis.2020.01.008.

Pan Z, Luo Y, Xia Y, Zhang X, Qin Y, Liu W, Li M, Liu X, Zheng Q, Li D. 2020. Cinobufagin induces cell cycle arrest at the S phase and promotes apoptosis in nasopharyngeal carcinoma cells. *Biomedicine & Pharmacotherapy* **122**:109763 DOI 10.1016/j.biopharm.2019.109763.

Qin H, Chen H, Zou Y, Zhang X, Wei C, Chen W, Xie Z, Yao M, Han B. 2019. Systematic investigation of the mechanism of Cichorium glandulosum on type 2 diabetes mellitus accompanied with non-alcoholic fatty liver rats. *Food & Function* **10**(5):2450–2460 DOI 10.1039/c8fo02284d.

Santulli G, Iaccarino G. 2016. Adrenergic signaling in heart failure and cardiovascular aging. *Maturitas* **93**:65–72 DOI 10.1016/j.maturitas.2016.03.022.
Shannon P, Markiel A, Ozier O, Baliga NS, Wang J, Ramage D, Amin N, Schwikowski B, Ideker T. 2003. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Research* 13(11):2498–2504 DOI 10.1101/gr.1239303.

Sousa LQ, Machado KD, Oliveira SF, Araújo LD, Monção Filho ED, Melo-Cavalcante AA, Vieira-Júnior GM, Ferreira PM. 2017. Bufadienolides from amphibians: a promising source of anticancer prototypes for radical innovation, apoptosis triggering and Na(+)/K(+)-ATPase inhibition. *Toxicon* 127:63–76 DOI 10.1016/j.toxicon.2017.01.004.

Strauss M, Smith W, Fedorova OV, Schutte AE. 2019. The Na(+)/K(+)-ATPase inhibitor marinobufagenin and early cardiovascular risk in humans: a review of recent evidence. *Current Hypertension Reports* 21(5):Article 38 DOI 10.1007/s11906-019-0942-y.

Tao J, Mao L, Zhou B, Liu Q, Yang A, Wei G, Liu R, Zhang W, Xu W, Ye J. 2017. Simultaneous determination of ginsenosides and bufadienolides in rat plasma after the oral administration of Shexiang Baoxin Pill for pharmacokinetic study by liquid chromatography tandem mass spectrometry following solid-phase extraction. *Biomedical Chromatography* 31(3):e3816 DOI 10.1002/bmc.3816.

Šeflová J, Čechová P, Biler M, Hradil P, Kubala M. 2017. Inhibition of Na+/K+-ATPase by 5, 6, 7, 8-tetrafluoro-3-hydroxy-2-phenylquinolin-4(1H)-one. *Biochimie* 138:56–61 DOI 10.1016/j.biochi.2017.04.009.

Wang Z, Sun L, Heinbockel T. 2014. Resibufogenin and cinobufagin activate central neurons through an ouabain-like action. *PLOS ONE* 9(11):e113272 DOI 10.1371/journal.pone.0113272.

Wei W, An Y, Zhang Y, Li Z, Zhou Y, Lei M, Zhang J, Qu H, Da J, Wu W, Guo D. 2020. Quantitative analysis of fourteen bufadienolides in *Venenum Bufonis* crude drug and its Chinese patent medicines by ultra-high performance liquid chromatography coupled with tandem mass spectrometry. *Journal of Ethnopharmacology* 251:Article 112490 DOI 10.1016/j.jep.2019.112490.

Wei W, Hou J, Wang X, Yu Y, Li H, Li Z, Feng Z, Qu H, Wu W, Guo D. 2019. *Venenum Bufonis*: an overview of its traditional use, natural product chemistry, pharmacology, pharmacokinetics and toxicology. *Journal of Ethnopharmacology* 237:215–235 DOI 10.1016/j.jep.2019.03.042.

Wu S, Hsiao Y, Kuo C, Yu F, Hsu S, Wu P, Chen J, Hsia T, Liu H, Hsu W, Chung J. 2015. Bufalin inhibits NCI-H460 human lung cancer cell metastasis in vitro by inhibiting MAPKs, MMPs, and NF-κB pathways. *The American Journal of Chinese Medicine* 43(6):1247–1264 DOI 10.1142/s0192415x15500718.

Xia X, Jin H, Yan S, Zhang W. 2010. Analysis of the bioactive constituents of ChanSu in rat plasma by high performance liquid chromatography with mass spectrometric detection. *Journal of Pharmaceutical and Biomedical Analysis* 53(3):646–654 DOI 10.1016/j.jpba.2010.05.009.

Xin X, Dong P, Sun X, Deng S, Zhang N, Wang C, Huo X, Li Y, Lan R, Chen L, Fan G. 2016. Identification of the hydroxylated derivatives of bufalin: phase I
metabolites in rats. *Journal of Asian Natural Products Research* **18**(3):239–247 DOI 10.1080/10286020.2015.1071358.

Xu S, Wang Y, Yu M, Wang D, Liang Y, Chen Y, Liao C, Xie Z, Zhao B, Han J, Duan Y, Yang X. 2020. LongShengZhi capsule inhibits doxorubicin-induced heart failure by anti-oxidative stress. *Biomedicine & Pharmacotherapy* **123**:Article 109803 DOI 10.1016/j.biopharma.2019.109803.

Yang L, Li A, Chen M, Yan Y, Liu Y, Li K, Jia J, Qin X. 2020a. Comprehensive investigation of mechanism and effective ingredients of Fangji Huangqi Tang by serum pharmacochemistry and network pharmacology. *Biomedical Chromatography* **34**(4):e4785 DOI 10.1002/bmc.4785.

Yang Y, Shi C, Xie J, Dai J, He S, Tian Y. 2020b. Identification of potential dipeptidyl peptidase (DPP)-IV inhibitors among Moringa oleifera phytochemicals by virtual screening, molecular docking analysis, ADME/T-based prediction, and in vitro analyses. *Molecules* **25**(1):Article 189 DOI 10.3390/molecules25010189.

Yu G, Luo Z, Zhou Y, Zhang L, Wu Y, Ding L, Shi Y. 2019. Uncovering the pharmacological mechanism of Carthamus tinctorius L. on cardiovascular disease by a systems pharmacology approach. *Biomedicine & Pharmacotherapy* **117**:Article 109094 DOI 10.1016/j.biopha.2019.109094.

Yu G, Wang W, Wang X, Xu M, Zhang L, Ding L, Guo R, Shi Y. 2018. Network pharmacology-based strategy to investigate pharmacological mechanisms of Zuojinwan for treatment of gastritis. *BMC Complementary and Alternative Medicine* **18**(1):292–292 DOI 10.1186/s12906-018-2356-9.

Yu G, Zhang Y, Ren W, Dong L, Li J, Geng Y, Zhang Y, Li D, Xu H, Yang H. 2016. Network pharmacology-based identification of key pharmacological pathways of Yin-Huang-Qing-Fei capsule acting on chronic bronchitis. *International Journal of Chronic Obstructive Pulmonary Disease* **12**:85–94 DOI 10.2147/COPD.S121079.

Yun HR, Yoo HS, Shin DY, Hong SH, Kim J-H, Cho CK, Choi YH. 2009. Apoptosis induction of human lung carcinoma cells by Chan Su (Venenum Bufonis) through activation of caspases. *Journal of Acupuncture and Meridian Studies* **2**(3):210–217 DOI 10.1016/S2005-2901(09)60057-1.

Zhang X, Pi Z, Zheng Z, Liu Z, Song F. 2018. Comprehensive investigation of in-vivo ingredients and action mechanism of iridoid extract from Gardeniae Fructus by liquid chromatography combined with mass spectrometry, microdialysis sampling and network pharmacology. *Journal of Chromatography B* **1076**:70–76 DOI 10.1016/j.jchromb.2018.01.023.

Zhang Z, Yi P, Yang J, Huang J, Xu P, Hu M, Zhang C, Wang B, Peng W. 2020. Integrated network pharmacology analysis and serum metabolomics to reveal the cognitive improvement effect of Bushen Tiansui formula on Alzheimer’s disease. *Journal of Ethnopharmacology* **249**:Article 112371 DOI 10.1016/j.ejp.2019.112371.

Zhu Z, Deng S, Liu D, Zhang BJ, Sun HZ, Tian Y, Wang CY, Wang L, Ma X. 2013. Isolation and identification of phase I metabolites of resibufogenin in rats. *Xenobiotica* **43**(5):479–485 DOI 10.3109/00498254.2012.728728.